Mark J Foley Revance Therapeutics, Inc. (RVNC) insider trading activity

Mark J Foley is President & CEO of Revance Therapeutics, Inc.. Currently has a direct ownership of 0 shares of RVNC, which is worth approximately $0. The most recent transaction as insider was on Feb 06, 2025, when has been sold 112,619 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Mark J Foley Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 06 2025	SELL Sale (or disposition) back to the issuer	-	112,619 Reduced 100.0%	0 Common Stock
Feb 06 2025	BUY Grant, award, or other acquisition	-	84,686 Added 50.0%	84,686 Common Stock
Feb 04 2025	SELL Disposition due to a tender of shares in a change of control transaction	$3,638,812 $3.65 p/Share	996,935 Reduced 97.27%	27,933 Common Stock
Feb 03 2025	BUY Grant, award, or other acquisition	-	27,933 Added 2.65%	1,024,868 Common Stock
Dec 31 2024	BUY Grant, award, or other acquisition	$2,180 $2.18 p/Share	1,000 Added 0.1%	996,935 Common Stock
Jun 30 2024	BUY Grant, award, or other acquisition	$2,180 $2.18 p/Share	1,000 Added 0.1%	995,935 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$108,824 $5.3 p/Share	20,533 Reduced 2.02%	994,935 Common Stock
Mar 06 2024	BUY Open market or private purchase	$209,400 $6.98 p/Share	30,000 Added 2.87%	1,015,468 Common Stock
Feb 29 2024	BUY Grant, award, or other acquisition	-	70,750 Added 6.7%	985,468 Common Stock
Dec 31 2023	BUY Grant, award, or other acquisition	$1,972 $7.47 p/Share	264 Added 0.03%	914,718 Common Stock
Aug 11 2023	SELL Payment of exercise price or tax liability	$908,890 $18.91 p/Share	48,064 Reduced 4.99%	914,454 Common Stock
Aug 11 2023	BUY Grant, award, or other acquisition	-	122,143 Added 11.26%	962,518 Common Stock
Aug 03 2023	SELL Open market or private sale	$593,117 $22.57 p/Share	26,279 Reduced 3.03%	840,375 Common Stock
Jul 03 2023	SELL Open market or private sale	$655,398 $24.94 p/Share	26,279 Reduced 2.94%	866,654 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	$15,610 $15.61 p/Share	1,000 Added 0.11%	892,933 Common Stock
Jun 09 2023	SELL Open market or private sale	$960,890 $30.72 p/Share	31,279 Reduced 3.39%	891,933 Common Stock
May 15 2023	SELL Open market or private sale	$2,433,943 $34.55 p/Share	70,447 Reduced 7.09%	923,212 Common Stock
Mar 15 2023	SELL Payment of exercise price or tax liability	$163,701 $30.65 p/Share	5,341 Reduced 0.65%	818,010 Common Stock
Mar 09 2023	SELL Open market or private sale	$2,223,620 $31.59 p/Share	70,390 Reduced 7.88%	823,351 Common Stock
Dec 31 2022	BUY Grant, award, or other acquisition	$7,368 $12.18 p/Share	605 Added 0.08%	718,092 Common Stock
Oct 13 2022	SELL Payment of exercise price or tax liability	$1,328,920 $26.97 p/Share	49,274 Reduced 6.43%	717,487 Common Stock
Sep 22 2022	BUY Grant, award, or other acquisition	-	175,649 Added 16.43%	893,741 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$11,750 $11.75 p/Share	1,000 Added 0.13%	766,761 Common Stock
Mar 15 2022	SELL Payment of exercise price or tax liability	$52,170 $15.79 p/Share	3,304 Reduced 0.43%	765,761 Common Stock
Feb 02 2022	BUY Grant, award, or other acquisition	-	175,649 Added 15.02%	993,659 Common Stock

Also insider at

GKOS

GLAUKOS Corp Healthcare

MJF

Mark J Foley

President & CEO

Nashville, TN

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RVNC shares.

Notify only if

Value

Insider Trading

Get notified when an Revance Therapeutics, Inc. insider buys or sells RVNC shares.

Notify only if

Operation

Value

Type

News

Receive news related to Revance Therapeutics, Inc.

Track Activities on RVNC

Account